Skip to content

ArriVent BioPharma

US · AVBP #3057 by market cap Listed 2024
10.52 -0.74 -6.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Quant vs Street three independent views, side by side

StockVane factor grade
C
Momentum strategy signal
Strong Sell
Analyst consensus
Buy

Signals diverge - worth digging into why.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 10 analysts

Buy
Avg price target 28.00 +166.2%
Price target rangecurrent 10.52
Low22.00
Avg28.00
High43.00
Buy 100% Hold 0% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-11 Citi -- Buy 23.00
2026-11-10 JonesTrading -- Buy 22.00
2026-11-10 Truist Financial -- Buy 24.00
2026-11-10 Citi -- Buy 23.00
2026-11-10 H.C. Wainwright -- Buy 27.00
2026-11-10 Oppenheimer -- Buy 25.00
2026-11-09 BTIG -- Buy 29.00
2026-10-28 H.C. Wainwright -- Buy 27.00
2026-10-27 Truist Financial -- Buy 21.00
2026-10-26 BTIG -- Buy 29.00
2026-10-26 Truist Financial -- Buy 21.00
2026-10-26 Guggenheim -- Buy 30.00
2026-10-26 Oppenheimer -- Buy 25.00
2026-10-25 BTIG -- Buy 29.00
2026-10-25 Clear Street -- Buy --
2026-10-23 Citi -- Buy 20.00
2026-10-20 B. Riley Securities -- Buy 29.00
2026-10-13 H.C. Wainwright -- Buy 27.00
2026-10-08 H.C. Wainwright -- Buy 27.00
2026-10-07 Citi -- Buy 20.00
2026-10-06 BTIG -- Buy 29.00
2026-09-15 Truist Financial -- Buy --
2026-09-15 Guggenheim -- Buy 45.00
2026-09-14 LifeSci Capital -- Buy 43.00
2026-09-14 Citi -- Buy 40.00

Price target trend monthly average, last 3 years

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ArriVent BioPharma discussion 0 comments

Add a comment